SCHEMBL4773067

SCHEMBL4773067

c1ccc(-c2nc(NCc3ncc[nH]3)cc(-c3cccnc3)n2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 0.50
CYP2C9 P11712 2/20 0.50
SLC2A1 P11166 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP1A2 P05177 8/20 0.45
CYP2D6 P10635 7/20 0.45
CLK4 Q9HAZ1 7/20 0.45
HSD17B10 Q99714 5/20 0.45
ALDH1A1 P00352 4/20 0.45
CYP2C19 P33261 5/20 0.43
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TSHR P16473 3/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
HIF1A Q16665 1/20 0.42
PPP1CA P62136 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4790942 0.83 CYP3A4 (0.48) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL2239929 0.83 CYP3A4 (0.65) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL4771527 0.83 CYP3A4 (0.55) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL4775842 0.83 CYP3A4 (0.60) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL4775067 0.82 CYP3A4 (0.57) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL4771758 0.82 ADORA1 (0.43) CYP2A6SMN1; SMN2TSHRNPC1TP53
SCHEMBL2238378 0.81 CYP3A4 (0.46) CYP3A4CYP2C9CYP2A6CYP1A2CYP2D6
SCHEMBL2241706 0.81 CYP3A4 (0.46) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL2240050 0.80 CYP3A4 (0.46) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2
SCHEMBL2240341 0.80 CDK4 (0.50) CYP3A4CYP2C9SLC2A1CYP2A6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed